Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Management of Late-Life Depression: Focus on Comorbid Conditions
By Warren D. Taylor, MD, and K. Ranga Rama Krishnan, MB, ChB
New Developments in Depression and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
New Developments in the Neurobiological Basis of Anxiety Disorders
By Jack M. Gorman, MD, Robert M. A. Hirschfeld, MD, and Philip T. Ninan, MD
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD
Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required
By Robert M. Nevels, Samuel T. Gontkovsky, Bryman E. Williams
Placebo Response in Depression: A Perspective for Clinical Practice
By Arif Khan, Shirin Khan